Stem Cell/Cord Blood Banking Market Report 2025

The stem cell/cord blood banking market size has grown strongly in recent years. It will grow from $12.26 billion in 2024 to $13.36 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to medical advancements, increased awareness, successful clinical applications, regulatory support, research funding.

The stem cell/cord blood banking market size is expected to see rapid growth in the next few years. It will grow to $21.78 billion in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to personalized medicine, emerging therapies, international expansion, investment in biotechnology, legal and ethical framework. Major trends in the forecast period include non-invasive collection methods, multiple banking services, transparency and regulation, collaborative efforts, storage innovations.

Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated by stem cell transplant. In stem cell transplant, treatment can be either done by autologous transplant in which the stem cells come from the same person who gets the transplant or by allogeneic transplant in which means the stem cells come from a matched related or unrelated donor. By using stem cells in the treatment of cancer, the blood forming stem cells which are damaged during chemotherapy can be restored. For instance, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023, reflecting a growth of 3.16% from 1,898,160 in 2021. Thus, increasing number of cancer patients is driving the growth of the stem cell /cord blood banking market.

The growing prevalence of chronic diseases is expected to drive the expansion of the stem cell/cord blood banking market in the coming years. Chronic diseases are long-term illnesses that persist for three months or more and may worsen over time. Since effective treatments for many chronic conditions are limited, the regenerative potential of stem cells and cord blood is being increasingly explored for therapeutic applications. Stem cell transplants, personalized medicine, and clinical research into new treatments for chronic conditions are all on the rise, leading to higher demand for banking services. For example, in February 2024, the World Health Organization, based in Switzerland, projected that by 2050, there would be over 35 million new cancer cases, a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of chronic diseases is fueling the growth of the stem cell and cord blood banking market.

An emerging trend in the stem cell/cord blood banking market is the pairing of cord blood and tissue storage with genetic testing services. This pairing offers complimentary services to existing clients, expanding their product portfolios. For instance, genetic testing company Natera introduced the Evercord cord blood and tissue storage service, enabling expectant parents to collect, store, and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications.

Major companies operating in the stem cell/cord blood banking market are developing peripheral blood stem cell processing and storage services to gain a competitive advantage. This involves the collection, processing, testing, and cryopreservation of hematopoietic stem cells (HSCs) obtained from a patient's peripheral blood. Cordlife Group Limited, a Singapore-based healthcare company, launched a new peripheral blood stem cell (PBSC) processing and storage service in Singapore in February 2023. This service supports patients requiring hematopoietic stem cell transplantation for various blood-related diseases, including leukemia, myeloma, and lymphoma. Cordlife collaborates with the Centre for Clinical Hematology (CFCH) to offer eligible patients stem cell mobilization and harvesting, with Cordlife handling the subsequent processing, testing, and cryopreservation of PBSCs. This new service aims to improve treatment outcomes for individuals requiring hematopoietic stem cell transplants in Singapore.

In July 2024, Cytomed Therapeutics, a Singapore-based biopharmaceutical company, acquired Cellsafe International Sdn Bhd for US $490,000. This acquisition is aimed at reinforcing its strategy to develop allogeneic, off-the-shelf donor-derived gamma delta (γδ) T cell therapies for the treatment of solid and liquid cancers. Cellsafe International Sdn Bhd is a Malaysia-based cord blood bank company.

Stem cell or cord blood banking is the practice of storing stem cells or blood obtained from the umbilical cord, with the aim of using them in the future for medical treatment. By extracting stem cells from the placenta and umbilical cord and preserving them, cord blood banking holds the potential to save lives through regenerative medicine.

The primary cell types involved in stem cell and cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells. Adult stem cells are a relatively rare group of cells found in the body during most of postnatal life. They have the capacity to generate a limited number of mature cell types specific to the tissue in which they are located. The various services provided in this field encompass collection, processing, analysis, and storage. These services are offered by different types of banks, including private banks and public banks. The applications for stem cell and cord blood banking are diverse and include conditions such as leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes, and many others.

The stem cell/cord blood banking market research report is one of a series of new reports that provides stem cell/cord blood banking market statistics, including stem cell/cord blood banking industry global market size, regional shares, competitors with a stem cell/cord blood banking market share, detailed stem cell/cord blood banking market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell/cord blood banking industry. This stem cell/cord blood banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the stem cell/cord blood banking market include AMAG Pharmaceuticals Inc., Cryo-Cell International Inc., Esperite NV, Americord Registry LLC, China Cord Blood Corporation, Cordlife Group Ltd., CordVida, Cryo Stemcell, PerkinElmer Inc., ReeLabs Pvt Ltd., Smart Cells International Ltd., Stemade Biotech Pvt Ltd., ViaCord Inc., Americord Registry LLC, LifeCell International, Cryoviva Biotech Pvt Ltd., Cytori Therapeutics Inc., Thermo Fisher Scientific Inc., Cord Blood America Inc., StemCyte Inc., Brainstorm Cell Therapeutics Inc., Cord Blood Registry Systems Inc., Healthbanks Biotech Usa Inc., Cryo-save Private Ltd., New York Cord Blood Center, CryoHoldco, Vita 34 International AG, Reliance Life Sciences Pvt Ltd., Maze Cord Blood Laboratories, Cells4Life Group LLP.

North America was the largest region in the stem cell/cord blood banking market in 2024. Western Europe was the second largest region in the stem cell/cord blood banking market analysis. The regions covered in the stem cell/cord blood banking market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell/cord blood banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stem cell/cord blood banking global market includes revenues earned by entities by providing services such as cryopreservation and collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.